Concord Biotech

Concord Biotech EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Concord Biotech (CONCORDBIO.NS) as of Oct 19, 2026 is 3.45 B INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 6.56 B INR — a change of -47.45% (lower).

EBITDA

3.45 BINR

YoY

-47.45%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Concord Biotech is 2026 3.45 B INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Concord Biotech was 2025 6.56 B INR. It decreases by -47.45% lower compared to the previous year.

The Concord Biotech EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
3.33 B INR
Jan 1, 2021
4.58 B INR
Jan 1, 2022
4.66 B INR
Jan 1, 2023
5.72 B INR
Jan 1, 2024
5.75 B INR
Jan 1, 2025
6.56 B INR
Jan 1, 2026
3.45 B INR
The Concord Biotech EBITDA history
YEAREBITDAYoY
3.45 BINR-47.45%
6.56 BINR+14.18%
5.75 BINR+0.49%
5.72 BINR+22.67%
4.66 BINR+1.91%
4.58 BINR+37.37%
3.33 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Concord Biotech Stock analysis

What does Concord Biotech do? Concord Biotech Ltd is a pharmaceutical company headquartered in Ahmedabad, India. It operates in the Health Care sector with a focus on Pharmaceuticals. The company went public via an IPO on August 18, 2023. Concord Biotech develops and manufactures active pharmaceutical ingredients (APIs) using fermentation and semi-synthetic processes. It produces finished formulations and APIs for therapeutic areas including immunosuppressants, anti-bacterial, oncology, and anti-fungal treatments. The company's API portfolio includes Mycophenolate Mofetil, Cyclosporine, Vancomycin Hydrochloride, and others. It also has a pipeline of API products under development such as Polymyxin B and Fidaxomicin. Concord Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Concord Biotech stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Concord Biotech is 3.45 B INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Concord Biotech changed from 6.56 B INR to 3.45 B INR, representing a -47.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Concord Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Concord Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Concord Biotech

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Concord Biotech